Glioblastoma Gelişimi, Tanı ve Tedavisinde Eksozomların Rolü

Yıl 2024, Cilt: 5 Sayı: 3, 93 - 100, 31.07.2024

Varol Güler , Sacide Pehlivan

Öz

Glioblastoma multiforme (GBM) yetişkinlerde görülen en
agresif ve tedaviye dirençli primer beyin tümörlerinden biridir. Son yıllarda, hücreler arası iletişimde rol oynayan küçük
hücre dışı veziküller olan eksozomlar, kanser ilerlemesi ve
tedavi direncindeki rolleri nedeniyle büyük ilgi görmektedir.
Glioblastoma kaynaklı eksozomlar, tümör hücreleri, stromal
hücreler ve bağışıklık hücreleri arasında çift yönlü sinyalleşmeyi kolaylaştırarak, tümör mikroçevresinde hücreler arası
iletişimin kilit aracıları olarak ortaya çıkmaktadır. Bu eksozomlar, tümör biyolojisinin çeşitli yönlerini kolektif bir şekilde modüle eden proteinler, nükleik asitler ve lipidler dahil
olmak üzere çeşitli biyoaktif molekül kargoları taşır. Bu moleküllerin eksozom yolu ile transferi hedef hücrede proliferasyonunu, invazyonunu, anjiyogenezi, immün baskılanmayı
ve tedavi direncini teşvik eder. Bununla birlikte, glioblastomadan elde edilen eksozomlar, tanısal ve prognostik öneme
sahip zengin bir biyomolekül repertuvarı barındırır. Ayrıca,
eksozomlar glioblastoma tedavisi için umut verici terapötik
yollar da sunmaktadır. Küçük moleküllü ilaçlar, nükleik asitler ve immünomodülatör moleküller de dahil olmak üzere
terapötik kargoları tümör hücrelerine hedefli olarak iletmek
üzere tasarlanabilirler. Sonuç olarak, eksozomların glioblastom ilerlemesi, teşhisi ve tedavisindeki rollerinin anlaşılması,
kişiselleştirilmiş tıp için yeni terapötik stratejiler ve biyobelirteçler hakkında bir bilgi birikimi sağlar ve nihayetinde bu
zorlu hastalıkta hasta sonuçlarını iyileştirmeyi amaçlar. Bu
derleme, glioblastoma ve eksozomlar arasındaki çok yönlü
etkileşimin tümör ilerlemesi, tanı ve terapötik stratejilere katkılarına ışık tutmaktadır.

Anahtar Kelimeler

Glioblastoma, eksozom, glioma, ilaç direnci

Kaynakça

• 1. Reuss DE. Updates on the WHO diagnosis of IDH-mutant glioma. J Neurooncol. 2023; 162(3):461–9. Doi: 10.1007/S11060-023-04250-5/FIGURES/2.
• 2. Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of Glioblastoma Multiforme–Literature Review. Cancers 2022, Vol 14, Page 2412. 2022; 14(10):2412. doi: 10.3390/CANCERS14102412.
• 3. Luo C, Song K, Wu S, Hameed NUF, Kudulaiti N, Xu H, et al. The prognosis of glioblastoma: a large, multifactorial study. Br J Neurosurg. 2021; 35(5):555–61. doi: 10.1080/02688697.2021.1907306.
• 4. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science (80- ). 2020; 367(6478). doi: 10.1126/SCIENCE.AAU6977/ASSET/F5050DD7-9124-4A75-9FBE-2BCDF3F27CD8/ASSETS/GRAPHIC/367_ AAU6977_F6.JPEG.
• 5. Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signaling. Cell Commun Signal 2021 191. 2021; 19(1):1–19. doi: 10.1186/S12964-021-00730-1.
• 6. Kenific CM, Zhang H, Lyden D. An exosome pathway without an ESCRT. Cell Res 2020 312. 2020; 31(2):105–6. doi: 10.1038/s41422-020-00418-0.
• 7. Luo M, Luan X, Jiang G, Yang L, Yan K, Li S, et al. The Dual Effects of Exosomes on Glioma: A Comprehensive Review. J Cancer. 2023; 14(14):2707. doi: 10.7150/ JCA.86996.
• 8. Wang M, Zhao Y, Yu ZY, Zhang R De, Li SA, Zhang P, et al. Glioma exosomalmicroRNA-148a-3p promotes tumor angiogenesis through activating the EGFR/ MAPK signaling pathway via inhibiting ERRFI1. Cancer Cell Int. 2020; 20(1):1– 16. doi: 10.1186/S12935-020-01566-4/FIGURES/6.
• 9. Xu X, Liu Y, Li Y, Chen H, Zhang Y, Liu J, et al. Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway. J Exp Clin Cancer Res. 2021; 40(1):1–20. doi: 10.1186/S13046-020- 01810-9/FIGURES/10.
• 10. Gu Q, Chen X, Zhou L, Liu X. Exosome EpCAM promotes the metastasis of glioma by targeting the CD44 signaling molecule on the surface of glioma cells. Adv Clin Exp Med. 2020; 29(11):1277. doi: 10.17219/ACEM/126051.
• 11. Colangelo NW, Azzam EI. Extracellular vesicles originating from glioblastoma cells increase metalloproteinase release by astrocytes: The role of CD147 (EMMPRIN) and ionizing radiation. Cell Commun Signal. 2020; 18(1):1–14. doi: 10.1186/S12964-019-0494-4/FIGURES/6.
• 12. Ahmadi M, Rezaie J. Tumor cells derived-exosomes as angiogenic agents: Possible therapeutic implications. J Transl Med. 2020; 18(1):1–17. Doi: 10.1186/S12967- 020-02426-5/FIGURES/5.
• 13. Wang Z, Yuan Y, Ji X, Xiao X, Li Z, Yi X, et al. The Hippo-TAZ axis mediates vascular endothelial growth factor C in glioblastoma-derived exosomes to promote angiogenesis. Cancer Lett. 2021; 513:1–13. doi: 10.1016/J.CANLET.2021.05.002.
• 14. Li J, Yuan H, Xu H, Zhao H, Xiong N. Hypoxic Cancer-Secreted Exosomal miR182-5p Promotes Glioblastoma Angiogenesis by Targeting Kruppel-like Factor 2 and 4. Mol Cancer Res. 2020; 18(8):1218–31. doi: 10.1158/1541-7786.MCR-19- 0725.
• 15. Yang ZJ, Bi QC, Gan LJ, Zhang LL, Wei MJ, Hong T, et al. Exosomes Derived from Glioma Cells under Hypoxia Promote Angiogenesis through Up-regulated Exosomal Connexin 43. Int J Med Sci. 2022; 19(7):1205–15. doi: 10.7150/ IJMS.71912.
• 16. Dai J, Jiang Y, Hu H, Zhang S, Chen Y. Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment. Pathol Oncol Res. 2024; 30:1611549.
• 17. Zhao G, Yu H, Ding L, Wang W, Wang H, Hu Y, et al. microRNA-27a-3p delivered by extracellular vesicles from glioblastoma cells induces M2 macrophage polarization via the EZH1/KDM3A/CTGF axis. Cell Death Discov 2022 81. 2022; 8(1):1–12. doi: 10.1038/s41420-022-01035-z.
• 18. Qian M, Wang S, Guo X, Wang J, Zhang Z, Qiu W, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways. Oncogene. 2020; 39(2):428–42. doi: 10.1038/S41388-019-0996-Y.
• 19. Hong S, You JY, Paek K, Park J, Kang SJ, Han EH, et al. Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment. Theranostics. 2021; 11(19):9687–704. doi: 10.7150/THNO.60851.
• 20. Liu X, Guo Q, Gao G, Cao Z, Guan Z, Jia B, et al. Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustainingErbB downstream signaling. J Nanobiotechnology. 2023; 21(1). doi: 10.1186/ S12951-023-01801-W.
• 21. Ma C, Nguyen HPT, Jones JJ, Stylli SS, Whitehead CA, Paradiso L, et al. Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression. Int J Mol Sci. 2022; 23(5). doi: 10.3390/ IJMS23052770.
• 22. Li Y, Chen J, Chen Z, Xu X, Weng J, Zhang Y, et al. CircGLIS3 Promotes High-Grade Glioma Invasion via Modulating Ezrin Phosphorylation. Front Cell Dev Biol. 2021; 9:663207.
• 23. Chai Y, Wu HT, Liang CD, You CY, Xie MX, Xiao SW. Exosomal lncrna ror1- as1 derived from tumor cells promotes glioma progression via regulating mir4686. Int J Nanomedicine. 2020; 15:8863–72. doi: 10.2147/IJN.S271795.
• 24. Tian Y, Gao X, Yang X, Chen S, Ren Y. Glioma-derived exosome Lncrna Agap2-As1 promotes glioma proliferation and metastasis by mediating Tgf-β1 secretion of myeloid-derived suppressor cells. Heliyon. 2024; 10(9):29949. doi: 10.1016/j.heliyon.2024.e29949.
• 25. Olioso D, Caccese M, Santangelo A, Lippi G, Zagonel V, Cabrini G, et al. Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study. Cancers 2021, Vol 13, Page 3006. 2021; 13(12):3006. doi: 10.3390/CANCERS13123006.
• 26. Yang Q, Wei B, Peng C, Wang L, Li C. Identification of serum exosomal miR98–5p, miR-183–5p, miR-323–3p and miR-19b-3p as potential biomarkers for glioblastoma patients and investigation of their mechanisms. Curr Res Transl Med. 2022; 70(1):103315.
• 27. Huang S, Liu L, Xu Z, Liu X, Wu A, Zhang X, et al. Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically. CNS Neurosci Ther. 2023; 29(12):3756–73. doi: 10.1111/CNS.14296.
• 28. Jones JJ, Nguyen H, Wong SQ, Whittle J, Iaria J, Stylli S, et al. Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma. Neuro-Oncology Adv. 2024; 6(1). doi: 10.1093/NOAJNL/VDAE027.
• 29. Maire CL, Fuh MM, Kaulich K, Fita KD, Stevic I, Heiland DiH, et al. Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. Neuro Oncol. 2021; 23(7):1087–99. doi: 10.1093/NEUONC/NOAB012.
• 30. Ma W, Zhou Y, Liu M, Qin Q, Cui Y. Long non-coding RNA LINC00470 in serum derived exosome: a critical regulator for proliferation and autophagy in glioma cells. Cancer Cell Int. 2021; 21(1):1–16. doi: 10.1186/S12935-021- 01825-Y/FIGURES/8.
• 31. Soltész B, Pös O, Wlachovska Z, Budis J, Hekel R, Strieskova L, et al. Mitochondrial DNA copy number changes, heteroplasmy, and mutations in plasma-derived exosomes and brain tissue of glioblastoma patients. Mol Cell Probes. 2022; 66:101875.
• 32. Li Y, Zheng X, Wang J, Sun M, Li D, Wang Z, et al. Exosomal circ-AHCY promotes glioblastoma cell growth via Wnt/β-catenin signaling pathway. Ann Clin Transl Neurol. 2023; 10(6):865–78. doi: 10.1002/ACN3.51743.
• 33. Khristov V, Lin A, Freedman Z, Staub J, Shenoy G, Mrowczynski O, et al. Tumor-Derived Biomarkers in Liquid Biopsy of Glioblastoma. World Neurosurg. 2023; 170:182–94.
• 34. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, et al. Exploring Predictors of Response to Dacomitinib in EGFR -Amplified Recurrent Glioblastoma . JCO Precis Oncol. 2020; (4):593–613. doi: 10.1200/ PO.19.00295/ASSET/IMAGES/LARGE/PO.19.00295TA7.JPEG.
• 35. Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015; 6(29):26971. doi: 10.18632/ONCOTARGET.4699.
• 36. Ding M, Xu Q, Jin X, Han Z, Jiang H, Sun H, et al. Novel exosome-related risk signature as prognostic biomarkers in glioblastoma. Front Immunol. 2023; 14:1071023. doi: 10.3389/FIMMU.2023.1071023/BIBTEX.
• 37. Lee H, Bae K, Baek AR, Kwon E Bin, Kim YH, Nam SW, et al. Glioblastoma‐ Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment. Pharmaceutics. 2022; 14(5):1002. doi: 10.3390/pharmaceutics14051002.
• 38. Hill ML, Chung SJ, Woo HJ, Park CR, Hadrick K, Nafiujjaman M, et al. Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma. ACS Appl Mater Interfaces. 2024; 16. doi: 10.1021/ ACSAMI.4C02364/ASSET/IMAGES/LARGE/AM4C02364_0006.JPEG.
• 39. Rahmani R, Kiani J, Tong WY, Soleimani M, Voelcker NH, Arefian E. Engineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme. J Drug Target. 2023; 31(3):310–9. doi: 10.1080/1061186X.2022.2152819.
• 40. Bao P, Gu HY, Ye JJ, He JL, Zhong Z, Yu AX, et al. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy. Adv Sci. 2024; 11(6):2306336. doi: 10.1002/ADVS.202306336.
• 41. Lee Y, Kim M, Ha J, Lee M. Brain-targeted exosome-mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti-tumor effects in glioblastoma animal models. Bioeng Transl Med. 2023; 8(2):e10426. doi: 10.1002/BTM2.10426.
• 42. Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q, et al. Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro Oncol. 2022; 24(11):1871–83. doi: 10.1093/NEUONC/NOAC071.
• 43. Mousavi SM, Hosseindoost S, Mahdian SMA, Vousooghi N, Rajabi A, Jafari A, et al. Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. Pathol - Res Pract. 2023; 245:154427.